Jan
11
2022
On demand

Cell and gene therapy matures: Streamlining and smoothing the path to commercialization

Sponsor
Cell and gene therapy matures: Streamlining and smoothing the path to commercialization

The cell and gene therapy (CGT) industry is coming of age with multiple approved products in both AAV and gene-modified cell therapy. As the field continues to grow and mature, the advantages of integrated products and solutions for therapeutic developers is becoming apparent. Typically CGT program development requires managing multiple relationships and this presents challenges in aligning timelines. In this talk learn how Charles River's portfolio of products and services helps to enable our partners to streamline their path to commercialization.

  • Snapshot of Charles River’s CGT development portfolio
  • An in-depth look at early activities including antibody generation and target screening (basal activity, on-target/off-target binding)
  • Cell supply considerations for autologous and allogeneic programs
  • Plasmid, vector, and cell therapy manufacturing overview

Matt Hewitt, PhD

Senior Director, Scientific Services, Cell and Gene Therapy, Charles River Laboratories

Matthew Hewitt, PhD, currently serves as Senior Director, Scientific Services, Cell and Gene Therapy (CGT) at Charles River Laboratories. Matt plays a critical role in driving CGT strategic vision as well as leading one of Charles River’s CGT sites.

Before joining the company, he was Head of R&D and Clinical Development for Lonza’s Personalized Medicine Business Unit where he led development of the Cocoon manufacturing technology, a closed, automated, scalable cell therapy manufacturing solution. In addition, he developed and executed numerous collaborations across academia and industry that leveraged the Cocoon technology. 

Prior to Lonza, Matt led the Tumor Immunology and Microenvironment program at Bellicum Pharmaceuticals, which focused on improving cell therapy efficacy in solid tumors. He also led the Immunology group at the University of Pennsylvania’s Gene Therapy Program, leading and contributing to numerous AAV gene therapy programs.

Matt received his PhD in Biophysics and Physiology from the University of Alabama at Birmingham and completed his postdoctoral fellowship at Johns Hopkins University.

SPEAKERS

Matt Hewitt, PhD
Matt Hewitt, PhD
Senior Director, Scientific Services, Cell and Gene Therapy, Charles River Laboratories

You might also like